AtriCure (NASDAQ:ATRC – Free Report) had its target price decreased by JPMorgan Chase & Co. from $51.00 to $46.00 in a ...

AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) dropped 6.8% during mid-day trading on Friday after Canaccord Genuity Group lowered their price target on the stock from $66.00 to $52.00.

Investors might want to bet on AtriCure (ATRC), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

BTIG raised the firm’s price target on AtriCure (ATRC) to $58 from $57 and keeps a Buy rating on the shares after the company’s Investor Day.

Karen Prange, a director at $ATRC, sold 6,100 shares of the company on 03-05-2025 for an estimated $232,531. We received data on the trade from a recent SEC filing ...

MASON, Ohio, March 12, 2025--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and ...

Across the recent three months, 11 analysts have shared their insights on AtriCure ATRC, expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their recent ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRC – Research Report) and Journey ...

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...